Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lazertinib
Pharma
Akeso-Summit, BIOSECURE, Candid and more—Fierce Pharma Asia
Akeso and Summit's ivonescimab handily beat Keytruda in a China phase 3 study. The House passed the BIOSECURE Act. Candid emerged with $370 million.
Angus Liu
Sep 13, 2024 8:53am
J&J builds case for Tagrisso rival with survival analysis
Sep 8, 2024 2:07pm
J&J-Yuhan, Merck, biosecurity—Fierce Pharma Asia
Aug 23, 2024 10:05am
J&J's Tagrisso challenger wins FDA nod in first-line lung cancer
Aug 20, 2024 10:26am
ESMO: Should AZ worry about J&J's Tagrisso head-to-head win?
Oct 23, 2023 10:30am
J&J notches Rybrevant trial win as Tagrisso showdown nears
Sep 6, 2023 11:35am
